InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of ... which sells contact lenses as well as ophthalmic pharmaceuticals, intraocular lenses, and eye surgery products ...

Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...

Bausch + Lomb moved to bolster the eye-care company's pipeline of clinical-stage offerings with the acquisition of Whitecap Biosciences, a firm developing two therapies for potential use in glaucoma ...

The pupillary dilation caused by phenylephrine and tropicamide can be reversed with dapiprazole hydrocloride (Rev-Eyes™, Storz Ophthalmic, a division of Bausch & Lomb, Rochester, NY) Dapiprazole ...

It seems like it was only 2 months ago that Miebo (perfluorohexyloctane ophthalmic solution, Bausch + Lomb) and Xdemvy (lotilaner ophthalmic solution 0.25%, Tarsus Pharmaceuticals) were approved ...

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at ...

The key players in the global ophthalmic lasers market include Alcon, Bausch + Lomb, Johnson & Johnson, NIDEK, and ZEISS. Furthermore, Alcon, a prominent player in the global healthcare sector ...

VAUGHAN, Ontario, January 13, 2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX ... founded in 2015 to develop novel therapies for ophthalmic diseases with a focus on glaucoma, GA ...

Bausch + Lomb Corporation (NYSE/TSX ... Whitecap Biosciences was founded in 2015 to develop novel therapies for ophthalmic diseases with a focus on glaucoma, GA and other serious eye diseases.